The 150 patients were randomized in a double-blinded fashion into 3 equal groups to receive immunomodulatory therapy with 8 mg/kg celecoxib ( group A ) , 0.4 mg/kg Sou-Medrol ( group B ) , or placebo ( group C ) , given daily from 5 days before surgery to 5 days after surgery , and the postoperative cancer recurrence were compared .